Amadeus Capital Partners

The Department for Science, Innovation and Technology (DSIT) announces a free AI Skills Boost programme, with courses designed to support 10m UK workers with key AI skills by 2030. This is a useful step in the right direction. In practice, adoption is being held back less by what models can do and more by whether teams feel confident using them day to day, in the workflows that actually matter. The programme expands free training to every UK adult via an AI Skills Hub, with short, practical modules (some designed to take under 20 minutes) and digital badges on completion. If we want AI to translate into durable competitiveness, the basics need to be widely distributed. Not just in large enterprises, but in the long tail of SMEs and public services where capacity is tight and the upside is tangible. 🔗 Read the full story and access the courses: https://lnkd.in/eQDsTrQp

Most AI in production still fails for the same two reasons: you cannot trust it, and you cannot explain it. At DLD Conference Munich 2026, William Tunstall-Pedoe FREng, founder and CEO of UnlikelyAI, put a useful frame on what is holding enterprise adoption back. Large language models are astonishing at language, images, and messy real-world data. But they are still, at heart, statistical guesses. They plateau before 100% accuracy, and their internals are a formula with hundreds of billions of weights that is hard to interrogate. Traditional software is the opposite: traceable, deterministic, and expected to be right every time (your spreadsheet does not get to be “mostly correct”). It also cannot handle open-ended language. Unlikely AI is taking a neurosymbolic route: combining LLMs with symbolic methods to get both capability and auditability. In regulated settings, that matters. William pointed to the widely cited figure that 95% of AI pilots never reach production, often because systems go wrong occasionally, and no one can justify why. There is also a practical upside: symbolic components run on CPUs and use a fraction of the power of GPU-heavy approaches. 🔗 Watch the full interview: https://lnkd.in/eftRSuXn

“This will be a multi-billion dollar business.” — That is Carmen Palacios-Berraquero in Sifted, on why Nu Quantum is building the networking layer for distributed quantum computing. The premise is straightforward: scaling quantum is unlikely to be a single monolithic machine story. It is more likely to be systems connected through a workable qubit photon interface and a practical way to create and manage entanglement across a network. Nu Quantum started in 2018 with single-photon devices, then made a deliberate pivot after extensive conversations across the sector about what “commercial scale” would actually require. In 2024, the team launched its first qubit photon interface prototype, followed by a quantum networking unit intended to act as a network hub. The article also notes $11m in revenues since 2023, alongside a continued focus on the technology roadmap. We have supported Nu Quantum since 2019 because deep infrastructure work is where real defensibility gets built. Congratulations to Carmen and the team on the feature. Article author: Daphné Leprince-Ringuet 🔗Read the article: https://lnkd.in/d4x76uAU

Our CEO Dame Anne Margaret Glover was invited by the British Private Equity & Venture Capital Association (BVCA) this week to attend a Royal reception at the Palace of Holyroodhouse in Edinburgh. Anne joined Scotland’s First Minister John Swinney MSP, Deputy First Minister Kate Forbes MSP, the BVCA team and other distinguished guests at the reception. Thank you to the BVCA for the invitation, and for bringing the UK venture community together. 📸 Photos from the reception below.

Nuclera has extended its Series C to $87m to speed up how quickly researchers can make, purify, and test antibodies in a single workflow. This announcement follows a $12m financing extension led by Elevage Medical Technologies and Jonathan Milner, with ongoing participation from British Business Bank and GK Goh. Nuclera is accelerating the integration of antibody expression and binding validation into eProtein Discovery, aiming for end-to-end full-format antibody capability across expression, purification, and binding validation on an integrated, high-throughput system. Since its 2024 Series C close, the team has expanded eProtein Discovery with a membrane protein workflow, broadened access across APAC and the Middle East, and started a collaboration with Cytiva to help shorten the path from DNA to purified, characterised proteins. We did not participate in this extension, but we are supportive of the progress and pleased to see the platform moving into one of the fastest-growing segments of biologics R&D. Congratulations to the Nuclera team! 🔗 Read the press release: https://lnkd.in/dZpgVV-3

Automating warehouses with robotics-as-a-service. 🦾 NEOintralogistics has secured a €3m seed round, led by the Amadeus APEX Technology Fund with strong participation from Cetus Holding. The team is building a Robotics-as-a-Service model for end-to-end warehouse picking automation: fast to deploy, designed to fit both existing (brownfield) sites and new-build (greenfield) operations, with a pay-per-pick approach that shifts automation from CapEx to a service. In practice, that can mean deployments in a few weeks, with the potential to cut manual labour requirements by up to 70%. The funding will support customer acquisition, product refinement, team growth, and international expansion. Read the press release: https://lnkd.in/gbs7jW7f

Congratulations to four Amadeus portfolio teams featured in The Sunday Times 100 Tech 2026. The list ranks the UK’s fastest-growing private tech companies on three-year revenue growth, split across Software and Hardware. We are proud to see:  • PolyAI ranked #12 in Software.  • Nyobolt ranked #17 in Hardware.  • XYZ Reality ranked #19 in Hardware.  • Riverlane featured in The Sunday Times AI Ones to Watch coverage. Different domains, same underlying pattern: ambitious technical targets, plus the discipline to make them real. Well done to the teams across all four companies. 🔗 Read the full list: https://lnkd.in/dCyAjxMn #SundayTimes100

This week, our CEO and co-founder, Anne Margaret Glover, was formally appointed a Dame Commander of the Order of the British Empire (DBE), recognised for contributions to science, engineering, and business in the UK. The investiture took place at Windsor Castle on 13 January 2026. After the ceremony, a celebration was held in London with family, close friends and colleagues to mark the occasion. Thank you to all who joined us. Dame Anne's influence has extended beyond venture capital over the past three decades. She has been a leading advocate for mobilising long-term capital to support science and engineering-based businesses in that time. Amadeus has backed more than 200 companies since 1997. That work has always sat at the intersection of research, entrepreneurship, and the harder problem: turning world-class science into enduring global businesses. 🔗 Read the press release: https://lnkd.in/gUrJBBJc

Britain’s biggest constraint is also one of our best design inputs. We keep meeting UK and European teams who assume the US playbook is the default: build for one large, homogeneous market first, then “go global” later. In deep tech, that logic often breaks down. A product optimised for a single set of consumers, regulations, and procurement norms can look strong at home, yet struggle elsewhere. Europe’s fragmentation and tighter capital environment force a different starting point: build from first principles, and design for interoperability early. You can see the pattern in places where Europe got ahead: ARM’s power efficiency, GSM’s standardisation, Bluetooth’s insistence on interoperability. And it is playing out now. PolyAI committed fully to voice AI for customer experience rather than hybrid text and voice approaches that map neatly to US workflows. OrganOx took a similarly pragmatic route by training hospital staff alongside deploying organ preservation systems globally. In our CEO and co-founder Dame Anne Margaret Glover's latest UKTN quarterly column, she sets out two practical suggestions: back conviction over consensus, and build for the world, including competing directly in the US market itself. 🔗 Read the full article: https://lnkd.in/ez_S8Y2F

In UK deep tech, “early-stage” can still mean board-level ambition and global pull. We have been investing in the UK, Europe and beyond for almost three decades, and one pattern is consistent: the companies that endure are built around real IP and know-how, then engineered into products that can win internationally. In this short video with Jonathan Moyes at Wealth Club, our Partner Amelia Armour shares how we think about that in the Amadeus Early-Stage EIS Fund, including how the EIS typically co-invests alongside our larger institutional funds, often entering in the second or third round via pre-emption rights. That matters because the main fund can take a meaningful stake and usually a board seat. Amelia grounds it with examples: • PolyAI, which started as a three-person team from Cambridge and now works with enterprises including Whitbread and Metro Bank (with more than 80% of revenue coming from the US). • Xampla, a Cambridge spin-out building a plant-based replacement for single-use plastics, designed for cost parity and drop-in manufacturing. • Ravelin Technology, a fraud prevention company sold to Worldpay in February 2025, after the EIS fund first invested in 2020. ❗Important: This post is not advice nor a research or personal recommendation to invest. If you’re unsure, please seek advice. Investments are for the long term. They are high risk and illiquid and can fall as well as rise in value: you could lose all the money you invest. 🔗 Watch the interview: https://lnkd.in/eHeyPj68